Search | Clinical Trials Finder

Conditions: Relapsing-remitting Multiple Sclerosis
Interventions: BAF312, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 297 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 16
States / cities: Cullman, Alabama • San Francisco, California • Centennial, Colorado + 13 more

Conditions: NMO Spectrum Disorder
Interventions: Acceptance and Commitment Therapy; Behavioral
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Neuromyelitis Optica
Interventions: Ravulizumab; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Neuromyelitis Optica Spectrum Disorder
Interventions: Inebilizumab; Drug
Lead sponsor: Amgen; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 4
States / cities: La Jolla, California • Loma Linda, California • Boston, Massachusetts + 1 more

Conditions: Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
Interventions: eculizumab; Biological
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 19
States / cities: Scottsdale, Arizona • Oceanside, California • Washington D.C., District of Columbia + 15 more

Conditions: Neuromyelitis Optica (NMO), NMO Spectrum Disorder (NMOSD)
Interventions: Satralizumab, Placebo, Baseline Treatment; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 12 Years to 74 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Transverse Myelitis, Neuromyelitis Optica, Idiopathic Transverse Myelitis, Myelitis NOS
Interventions: Dalfampridine, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Demyelinating Diseases, Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder Attack, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Optic Neuritis
Interventions: non-interventional study; Other
Lead sponsor: Experimental and Clinical Research Center, a cooperation between the Max Delbrück Center for Molecul; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 3
States / cities: Aurora, Colorado • Boston, Massachusetts • Rochester, Minnesota

Conditions: Neuromyelitis Optica Spectrum Disorder
Interventions: MR-C-014; Device
Lead sponsor: MedRhythms, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Atlanta, Georgia • Boston, Massachusetts

Conditions: Multiple Sclerosis, Neuromyelitis Optica, Demyelinating Autoimmune Diseases, CNS
Interventions: Not listed
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2034
U.S. locations: 1
States / cities: New York, New York

Conditions: Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive, Clinically Isolated Syndrome, Radiologically Isolated Syndrome, Neuromyelitis Optica Spectrum Disorders, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Neurologic Autoimmune Disease, Neurologic Disorder, Healthy Aging
Interventions: Not listed
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2041
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Neuromyelitis Optica Spectrum Disorder, NMOSD
Interventions: Satralizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 2 Years to 11 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
Interventions: Eculizumab; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: Not listed
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 15
States / cities: San Francisco, California • Washington D.C., District of Columbia • Miami, Florida + 11 more

Conditions: NMO Spectrum Disorder, Spasticity, Muscle
Interventions: Nabiximols, Placebo; Drug
Lead sponsor: Michael, Levy M.D.,Ph.D.; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
Interventions: Eculizumab, Placebo; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 19
States / cities: Scottsdale, Arizona • Carlsbad, California • Washington D.C., District of Columbia + 15 more

Conditions: Neuromyelitis Optica Spectrum Disorder
Interventions: satralizumab, azathioprine (AZA), mycophenolate mofetil (MMF), oral corticosteroids; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 13
States / cities: Birmingham, Alabama • Miami, Florida • Columbus, Georgia + 10 more

Conditions: Multiple Sclerosis, Transverse Myelitis, Neuromyelitis Optica, Acute Disseminated Encephalomyelitis, Optic Neuritis
Interventions: Not listed
Lead sponsor: Accelerated Cure Project for Multiple Sclerosis; Other
Eligibility: Not listed
Enrollment: 3,226 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2036
U.S. locations: 10
States / cities: Phoenix, Arizona • Stanford, California • Aurora, Colorado + 7 more

Conditions: NMOSD
Interventions: Rituximab (R), Eculizumab (Soliris®), Ravulizumab, Satralizumab, Inebilizumab; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Neuromyelitis Optica Spectrum Disorder, NMOSD
Interventions: Satralizumab 120 mg; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder Attack, Neuromyelitis Optica Spectrum Disorder Relapse, Neuromyelitis Optica Spectrum Disorder Progression, Optic Neuritis
Interventions: Reflex (Brightlamp Inc., Purdue University); Diagnostic Test
Lead sponsor: Jagannadha R Avasarala; Other
Eligibility: 18 Years to 90 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: B-cell Mediated Autoimmune Disorders
Interventions: Azercabtagene zapreleucel (azer-cel); Drug
Lead sponsor: TG Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 8
States / cities: La Jolla, California • Ann Arbor, Michigan • Omaha, Nebraska + 5 more

Conditions: Neuromyelitis Optica Spectrum Disorder
Interventions: Ravulizumab; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: Not listed
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 5
States / cities: Washington D.C., District of Columbia • Miami, Florida • Boston, Massachusetts + 2 more

Conditions: AQP4+ NMOSD
Interventions: CC-97540 (BMS-986353), Fludarabine, Cyclophosphamide, Tocilizumab; Biological · Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 60 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Neuromyelitis Optica (NMO), NMO Spectrum Disorder (NMOSD)
Interventions: Satralizumab, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 20
States / cities: Aurora, Colorado • Miami, Florida • Vero Beach, Florida + 17 more

Search by objective public record fields.

Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis

ACT with NMOSD Patients and Caregivers Pilot Study

Study of the Clinical and Radiological Impact of Ravulizumab in People With Neuromyelitis Optica Spectrum Disorder

Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder

An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients

Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)

Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch)

Acute Optic Neuritis Network: an International Study That Invesitages Subjects With a First-ever Episode of Acute Inflammation of the Optic Nerve

Acceptability and Safety of MR-C-014 in Persons With Neuromyelitis Optica Spectrum Disorder

Longitudinal Cortical Demyelination in Multiple Sclerosis and Related Disorders

MS-ResearchBiomarkerS

A Study to Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, and Pharmacodynamics of Satralizumab in Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)

A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder

A Phase IIb Study of Nabiximols for Spasticity Due to Neuromyelitis Optica Spectrum Disorders

A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study)

A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD)

Biobank For MS And Other Demyelinating Diseases

Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD

A Study In Neuromyelitis Optica Spectrum Disorder (NMOSD) With Satralizumab As An Intervention

Diagnosis of ON With or Without MS or NMOSD

A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders

Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD

A Safety and Tolerability Study of CC- 97540 (BMS-086353) in Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Patients

Efficacy and Safety Study of Satralizumab (SA237) as Monotherapy to Treat Participants With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)